Gilead Sciences | GILD - Equity Capital And Reserves

Stock Price
141.06
Daily Change
-0.23 -0.16%
Monthly
-6.83%
Yearly
33.24%
Q1 Forecast
140.61

Gilead Sciences reported $22.62B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
ALKERMES USD 1.82B 85.86M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Glaxosmithkline GBP 22.06B 360M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
J&J USD 78.47B 0 Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 8.65B 680M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novartis USD 46.13B 1.38B Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
United Therapeutics USD 7.1B 506M Dec/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025